Published in Nihon Hinyokika Gakkai Zasshi on May 01, 2003
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Laparoscopic radical nephroureterectomy: a multicenter analysis in Japan. Eur Urol (2009) 2.97
Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer (2009) 2.64
Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer. Urology (2009) 2.23
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol (2006) 1.78
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res (2002) 1.67
Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol (2004) 1.65
Curli fibers are required for development of biofilm architecture in Escherichia coli K-12 and enhance bacterial adherence to human uroepithelial cells. Microbiol Immunol (2005) 1.61
Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res (2004) 1.58
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol (2007) 1.58
Perioperative management of transurethral surgery for benign prostatic hyperplasia: a nationwide survey in Japan. Int J Urol (2011) 1.55
Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol (2008) 1.55
Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group. Int J Urol (2010) 1.51
Risk factors for new-onset overactive bladder in older subjects: results of the Fujiwara-kyo study. Urology (2012) 1.49
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol (2009) 1.47
Aggressive angiomyxoma in the scrotum expressing androgen and progesterone receptors. Int J Urol (2003) 1.47
A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci (2004) 1.44
One-stage repair of severe hypospadias using modified tubularized transverse preputial island flap with V-incision suture. J Pediatr Urol (2008) 1.43
Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet (2002) 1.43
Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth. J Urol (2012) 1.41
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis (2011) 1.39
Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy. Int J Urol (2012) 1.39
Anatomical features of periprostatic tissue and its surroundings: a histological analysis of 79 radical retropubic prostatectomy specimens. Jpn J Clin Oncol (2004) 1.38
Surgical outcome of laparoscopic radical prostatectomy: summary of early multiinstitutional experience in Japan. Int J Clin Oncol (2003) 1.38
Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int (2006) 1.36
Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol (2007) 1.34
Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett (2012) 1.32
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol (2010) 1.28
Holmium laser enucleation for prostatic adenoma: analysis of learning curve over the course of 70 consecutive cases. J Urol (2003) 1.26
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer (2011) 1.26
Discrepancy between local and central pathological review of radical prostatectomy specimens. J Urol (2010) 1.24
Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol (2004) 1.22
Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. J Magn Reson Imaging (2008) 1.22
Twist promotes tumor cell growth through YB-1 expression. Cancer Res (2008) 1.22
Bladder Cancer Working Group report. Jpn J Clin Oncol (2010) 1.21
Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth. Cancer Res (2009) 1.20
Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int (2002) 1.20
Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol (2010) 1.18
MR imaging of focal medullary sponge kidney: case report. Magn Reson Med Sci (2012) 1.18
Clusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res (2012) 1.17
Complication rates of ultrasound-guided prostate biopsy: a nation-wide survey in Japan. Int J Urol (2008) 1.16
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma. Clin Cancer Res (2006) 1.15
Prognostic significance of circulating tumor cells in patients with hormone refractory prostate cancer. J Urol (2009) 1.15
Prevalence of renal cell carcinoma: a nation-wide survey in Japan, 2002. Int J Urol (2007) 1.14
The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer. Mod Pathol (2011) 1.13
Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990-2000 in Japan. Eur Urol (2004) 1.13
The endoscopic surgical skill qualification system in urological laparoscopy: a novel system in Japan. J Urol (2006) 1.13
Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma. Cancer (2002) 1.12
Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther (2007) 1.11
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol (2013) 1.10
The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res (2002) 1.10
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
Clinicopathological review of 46 primary retroperitoneal tumors. Int J Urol (2007) 1.07
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol (2007) 1.06
Amino acid transporter LAT3 is required for podocyte development and function. J Am Soc Nephrol (2009) 1.06
Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR. Mol Endocrinol (2009) 1.06
Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology (2006) 1.06
Disease-causing missense mutations in NPHS2 gene alter normal nephrin trafficking to the plasma membrane. Kidney Int (2004) 1.04
A remarkable reduction in the susceptibility of Neisseria gonorrhoeae isolates to cephems and the selection of antibiotic regimens for the single-dose treatment of gonococcal infection in Japan. J Infect Chemother (2002) 1.04
Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep (2010) 1.04
Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol (2010) 1.04
Ca2+ sensitization in contraction of human bladder smooth muscle. J Urol (2004) 1.03
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res (2005) 1.03
Prediction of postoperative renal function by preoperative serum creatinine level and three-dimensional diagnostic image reconstruction in patients with renal cell carcinoma. Urology (2004) 1.02
Mitochondrial p32/C1QBP is highly expressed in prostate cancer and is associated with shorter prostate-specific antigen relapse time after radical prostatectomy. Cancer Sci (2011) 1.02
Toward the realization of a better aged society: messages from gerontology and geriatrics. Geriatr Gerontol Int (2012) 1.02
Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr (2007) 1.01
Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. Free Radic Biol Med (2011) 1.01
Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol (2011) 1.00
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. Prostate (2010) 1.00
Holmium laser enucleation of the prostate: comparison of outcomes according to prostate size in 97 Japanese patients. J Endourol (2007) 0.99
Gleason score correlation between biopsy and prostatectomy specimens and prediction of high-grade Gleason patterns: significance of central pathologic review. Urology (2010) 0.99
Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology (2010) 0.99
Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells. Int J Cancer (2003) 0.99
Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation. Clin Cancer Res (2010) 0.98
Analysis of the prognostic factors for overactive bladder symptoms following surgical treatment in patients with benign prostatic obstruction. Neurourol Urodyn (2009) 0.97
Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol (2010) 0.97
Adverse drug reactions of intravesical bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol (2005) 0.97
Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol (2011) 0.97
Urethral dysfunction in diabetic rats. J Urol (2004) 0.97
The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol (2011) 0.96
Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol (2008) 0.96
Laparoscopic management of urachal remnants in adulthood. Int J Urol (2006) 0.96
Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer (2002) 0.96
Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest (2005) 0.96